Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 7/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 5/20 | 1.00 |
| ▸ | BLM | P54132 | 4/20 | 1.00 |
| ▸ | TSHR | P16473 | 4/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.98 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.76 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.75 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.75 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.75 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butylscopolamine SCHEMBL29643439 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1BLMTSHRPMP22 | |
| Butylscopolamine SCHEMBL2446872 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1BLMTSHRPMP22 | |
| Butylscopolamine SCHEMBL2446869 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1BLMTSHRPMP22 | |
| Butylscopolamine SCHEMBL14672547 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1BLMTSHRPMP22 | |
| Butylscopolamine SCHEMBL155102 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1BLMTSHRPMP22 | |
| Butylscopolamine SCHEMBL16168163 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1BLMTSHRPMP22 | |
| Butylscopolamine SCHEMBL25292 | 0.99 | BLM (1.00) | CHRM2CHRM1BLMTSHRPMP22 | |
| Butylscopolamine SCHEMBL25291 | 0.99 | BLM (1.00) | CHRM2CHRM1BLMTSHRPMP22 | |
| Butylscopolamine SCHEMBL2441812 | 0.99 | BLM (1.00) | CHRM2CHRM1BLMTSHRPMP22 | |
| Butylscopolamine SCHEMBL10732357 | 0.99 | CHRM2 (0.98) | CHRM2CHRM1BLMTSHRPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3793518-B1 | AN ORAL TABLET FOR TASTE MASKING OF ACTIVE INGREDIENTS COMPRISING NON-DIRECTLY COMPRESSIBLE SUGAR ALCOHOL PARTICLES | FERTIN PHARMA AS (DK) | 2025-03-26 | — | — | EP | claimed |
| US-20250009663-A1 | Mouthwash For Oral Care Benefits | FERTIN PHARMA A/S (DK) | 2025-01-09 | — | — | US | claimed |
| US-12156943-B2 | Tablet dosage form for buccal absorption of active ingredients | FERTIN PHARMA A/S (DK) | 2024-12-03 | — | — | US | claimed |
| EP-4088716-B1 | AN ORAL TABLET FOR INDUCED SALIVA GENERATION | FERTIN PHARMA AS (DK) | 2024-10-16 | — | — | EP | claimed |
| US-12109312-B2 | Oral tablet for taste masking of active ingredients | FERTIN PHARMA A/S (DK) | 2024-10-08 | — | — | US | claimed |
| EP-3793533-B1 | A TABLET DOSAGE FORM FOR BUCCAL ABSORPTION OF ACTIVE INGREDIENTS | FERTIN PHARMA AS (DK) | 2023-07-05 | — | — | EP | claimed |
| EP-3793534-B1 | AN ORAL TABLET FOR DELIVERY OF ACTIVE INGREDIENTS TO THE GASTROINTESTINAL TRACT | FERTIN PHARMA AS (DK) | 2023-04-05 | — | — | EP | claimed |
| EP-4088716-A1 | AN ORAL TABLET FOR INDUCED SALIVA GENERATION | Fertin Pharma A/S (DK) | 2022-11-16 | — | — | EP | claimed |
| US-11260030-B2 | Oral tablet for delivery of active ingredients to the gastrointestinal tract | FERTIN PHARMA A/S (DK) | 2022-03-01 | — | — | US | claimed |
| US-20260144745-A1 | Sugar Free Soft Chew Tablets | FERTIN PHARMA A/S (DK) | 2026-05-28 | — | — | US | disclosed |
| US-20260144746-A1 | Protein Based Soft Chew Tablets | FERTIN PHARMA A/S (DK) | 2026-05-28 | — | — | US | disclosed |
| EP-4734952-A1 | ORAL TABLET WITH IMPROVED UNIFORMITY OF CONTENT OF ACTIVES | Fertin Pharma A/S (DK) | 2026-05-06 | — | — | EP | disclosed |
| US-12551439-B2 | Flowpack for oral delivery of active ingredients | FERTIN PHARMA A/S (DK) | 2026-02-17 | — | — | US | disclosed |
| US-20250325483-A1 | FLOWPACK WITH COMPOSITION FOR IMPROVED TASTE MASKING OF ACTIVES | FERTIN PHARMA AS (DK) | 2025-10-23 | — | — | US | disclosed |
| EP-4146166-A1 | MOUTHWASH FOR ORAL CARE BENEFITS | Fertin Pharma A/S (DK) | 2023-03-15 | — | — | EP | disclosed |
| EP-4146164-A1 | FLOWPACK FOR ORAL DELIVERY OF ACTIVE INGREDIENTS | Fertin Pharma A/S (DK) | 2023-03-15 | — | — | EP | disclosed |
| CN-112118833-B | Disintegrating oral tablets suitable for active pharmaceutical ingredients | 费尔廷制药公司 | 2023-03-03 | — | — | CN | disclosed |
| EP-4088716-A1 | AN ORAL TABLET FOR INDUCED SALIVA GENERATION | Fertin Pharma A/S (DK) | 2022-11-16 | — | — | EP | disclosed |
| EP-3773511-B1 | AN ORAL TABLET FOR INDUCED SALIVA GENERATION | FERTIN PHARMA AS (DK) | 2022-07-06 | — | — | EP | disclosed |
| US-11260030-B2 | Oral tablet for delivery of active ingredients to the gastrointestinal tract | FERTIN PHARMA A/S (DK) | 2022-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144745-A1 | Sugar Free Soft Chew Tablets | SI, TREH, SLC2A3 | CHRM2 142/4885CHRM1 196/4885BLM 3781/4885 |
| US-12551439-B2 | Flowpack for oral delivery of active ingredients | GCK, SLC2A8, SLC2A1 | CHRM2 2442/4885CHRM1 2559/4885BLM 4145/4885 |
| US-20260144746-A1 | Protein Based Soft Chew Tablets | CARHSP1, HIRA, HEATR6 | CHRM2 993/4885CHRM1 1117/4885BLM 4444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.